KAIROS PHARMA, LTD. Impairment of Intangible Assets, Finite-lived
KAIROS PHARMA, LTD. (KAPA) reported Impairment of Intangible Assets, Finite-lived of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-05-13
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for the quarter ending 2026-03-31 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for the quarter ending 2025-06-30 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for fiscal 2025 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00.
- KAIROS PHARMA, LTD. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $0.00 10-K · filed 2025-04-15 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |